Covered Outpatient Drugs Federal Final Rule. Medical Assistance (MA) Program Fee-for-Service (FFS) Pharmacy Reimbursement
|
|
- Jerome Elmer Parsons
- 6 years ago
- Views:
Transcription
1 Covered Outpatient Drugs Federal Final Rule Medical Assistance (MA) Program Fee-for-Service (FFS) Pharmacy Reimbursement 1
2 Background On February 1, 2016, the Centers for Medicare and Medicaid Services (CMS) published the Covered Outpatient Drug Final Rule (CMS-2345-FC) (81 FR 5170) The Final Rule includes changes that states need to address when determining their payment methodologies for covered outpatient drugs in the Fee-for-Service (FFS)* program *The provisions for reimbursement do not apply to MCOs. 2
3 Background, continued Changes required under the new federal rule: 1. Requires states to pay pharmacy providers based on the actual acquisition cost (AAC) of the drug plus a professional dispensing fee 2. Requires states to submit a state plan amendment (SPA) with any proposed changes in payment methodology by June 30, 2017 with an effective date of no later than April 1, Requires states to include a description of reimbursement of drugs dispensed by 340B entities and 340B contract pharmacies in the SPA 3
4 Executive Summary To comply with the federally required changes, DHS is proposing regulations to implement the following: Adopt an AAC payment methodology for ingredient cost Increase the dispensing fee to $7.00 4
5 Actual Acquisition Cost (AAC) The agency s determination of the pharmacy providers actual prices paid to acquire drug products marketed or sold by specific manufacturers Options to determine AAC: Conduct a state survey of retail pharmacy providers pricing Use a national survey, such as the National Average Drug Acquisition Cost (NADAC) Use published compendia prices, such as wholesale acquisition cost (WAC) with adjustments to reflect discounts and other price concessions commonly obtained by retail pharmacies Proposed Option: Adopt a lower of methodology that includes NADAC An adjusted WAC when no NADAC is available 5
6 AAC Reimbursement for Ingredient Cost Outpatient Pharmacies Current Reimbursement For Brand Drugs, the lower of: Provider s Usual & Customary (U&C) charge WAC + 3.2% AWP 14% For Generic Drugs, the lower of: Provider s U&C WAC + 0% AWP 25% CMS FUL State Maximum Allowable Cost (MAC) Proposed Reimbursement For Brand Drugs, the lower of: Provider s U&C NADAC or WAC 3.3% For Generic Drugs: the lower of: Provider s U&C NADAC or WAC 50.5% CMS FUL State MAC 6
7 AAC 340B Reimbursement for Ingredient Cost - Outpatient Pharmacies Current 340B Drug Reimbursement: For brand drugs, the lower of: Provider s U&C WAC + 3.2% AWP 14% For generic drugs, the lower of: Provider s U&C (same as above) WAC + 0% AWP 25% CMS FUL State Maximum Allowable Cost (MAC) Proposed 340B Drug Reimbursement: For brand drugs, the lower of: Provider s U&C, not to exceed the 340B ceiling price NADAC or WAC 3.3% For generic drugs, the lower of: Provider s U&C, not to exceed the 340B ceiling price NADAC or WAC 50.5% CMS FUL State MAC 7
8 Professional Dispensing Fee Incurred at the point of sale or service and pays for costs in excess of the ingredient cost of a covered outpatient drug each time a covered outpatient drug is dispensed. Includes only pharmacy costs associated with ensuring that possession of the appropriate covered outpatient drug is transferred to a Medicaid beneficiary. Options: A national survey, regional or neighboring state surveys, or a state-specific survey Approach: Engaged Mercer Government Human Services Consulting (Mercer) to conduct a study on Pennsylvania-specific provider costs associated with professionally dispensing covered outpatient prescription drugs to FFS beneficiaries. Result: Based on the analysis of surveyed responses, $7.00 represents the average cost of professional dispensing as defined by the final rule for pharmacies dispensing prescriptions to Medicaid FFS beneficiaries. 8
9 Next Steps The Department: Posted the slides and the Mercer PROFESSIONAL DISPENSING FEE (PDF) ANALYSIS FOR MEDICAID BENEFICIARIES PHARMACY SURVEY REPORT on the Department s website for public view Will submit proposed rulemaking to amend the current regulations in Title 55 of the Pennsylvania Code, Chapter 1121, by updating the payment methodology for covered outpatient drugs to reflect the CMS Medicaid Program; Covered Outpatient Drugs; Final Rule; 42 CFR Part 447; [CMS-2345-FC] Will post a link to the proposed rulemaking on the Department website upon publication in the Pennsylvania Bulletin Will submit a SPA to reflect changes in pharmacy payment methodology by June 30, 2017 Regulations will be effective with publication as final in the Pennsylvania Bulletin 9
10 Comments Interested persons are invited to submit written comments and questions to the Department at the following address: Please submit your comments and questions by April 27,
M E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G
H E A L T H W E A L T H C A R E E R M E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G O H I O D E P A R T M E N T O F M E D I C A I D December 6, 2016 Presenters
More informationDecember 15, 2017 (31 State SPAs)
New State SPAs Reimburse 340B Covered Entities at Actual Acquisition Cost: Creates Disincentives For 340B Entities to Choose the Lowest Cost Drugs December 15, 2017 (31 State SPAs) On January 21, 2016,
More informationPharmacy Stakeholder Meeting December 20, 2016
Pharmacy Stakeholder Meeting December 20, 2016 WELCOME & AGENDA 9:30 Introductions (TennCare) 9:40 Tennessee AAC Survey (Myers and Stauffer LC) CMS Covered Outpatient Drugs Final Rule (CMS-2345-FC) Actual
More informationTexas Vendor Drug Program. Pharmacy Provider Procedure Manual Pricing & Reimbursement. Effective Date. March 2018
Texas Vendor Drug Program Pharmacy Provider Procedure Manual Pricing & Reimbursement Effective Date March 2018 The Pharmacy Provider Procedure Manual (PPPM) is available online at txvendordrug.com/about/policy/manual.
More informationNCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work
NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January 2016 The Centers for Medicare & Medicaid Services (CMS) recently issued a 658-page, oftendelayed, final rule on the
More informationRE: Mercer Professional Dispensing Fee and Actual Acquisition Cost Analysis for Medi- Cal-Pharmacy Survey Report
February 8, 2017 Harry Hendrix, Chief Pharmacy Benefits Division Department of Health Care Services PO Box 997413 MS: 2000 Sacramento, CA 95899 RE: Mercer Professional Dispensing Fee and Actual Acquisition
More informationNational Council for Prescription Drug Programs
National Council for Prescription Drug Programs White Paper The Proper Use of the NCPDP Telecommunication Standard Version D.0 as it applies to the Implementation of Medicaid Reimbursement Methodologies
More informationOREGON HEALTH AUTHORITY
HEALTH WEALTH CAREER OREGON HEALTH AUTHORITY PROFESSIONAL DISPENSING FEE SURVEY February 2, 2017 Presenters Shawna Kittridge, Mercer Jim Cook, Mercer Ralph Magrish, Mercer Scott Banken, Mercer Deborah
More informationPharmacy services: payment for prescribed drugs.
ACTION: Original DATE: 01/13/2017 3:21 PM 5160-9-05 Pharmacy services: payment for prescribed drugs. (A) Definitions (1) "340B ceiling price" means the highest price allowed to be charged by a manufacturer
More informationMedicaid Prescription Drug Payment Reform
Medicaid Prescription Drug Payment Reform Spring 2006 NCSL Health Chairs Meeting John M. Coster, Ph.D., R.Ph. June 10, 2006 1 Community Retail Pharmacy In 2005, there were approximately 56,000 community
More informationPrescription Drug Pricing and Community Pharmacy NALEO Legislative Summit on Health October 21, 2017
Prescription Drug Pricing and Community Pharmacy NALEO Legislative Summit on Health October 21, 2017 Ronna Hauser, PharmD VP Pharmacy Affairs The strength of our numbers NCPA represents America's 22,000+
More informationArchived 12.1 THE BASIS FOR ESTABLISHING A RATE OF PAYMENT DETERMINING A FEE... 2
SECTION 12 - REIMBURSEMENT METHODOLOGY 12.1 THE BASIS FOR ESTABLISHING A RATE OF PAYMENT... 2 12.2 DETERMINING A FEE... 2 12.2.A LONG-TERM CARE DISPENSING FEE REQUIREMENTS... 3 12.2.B CREDITS ON MEDICATIONS
More informationAssuring Medicaid Patients Access to Pharmacy Services Through Adequate Dispensing Fees
January 25, 2012 Ms. Cindy Mann, Deputy Administrator and Director Center for Medicaid, CHIP and Survey & Certification Centers for Medicare & Medicaid Services Department of Health and Human Services
More informationPharmacy Acquisition Cost and Its Role in Contract Negotiating
Pharmacy Acquisition Cost and Its Role in Contract Negotiating Presented by: Todd Grover Glass Box Analytics August 23, 2017 Understanding Pharmacy Acquisition Cost (AC) Drives Relationship Pairs Pharmacy
More informationProposed MAC Legislation May Increase Costs Of Affected Generic Drugs By More Than 50 Percent. Prepared for
Proposed MAC Legislation May Increase Costs Of Affected Generic Drugs By More Than 50 Percent Prepared for April 2014 Executive Summary MAC (Maximum Allowable Cost) is a savings tool used by Medicare,
More informationProposed MAC Legislation May Increase Costs of Affected Generic Drugs By More Than 50 Percent. Prepared for
Proposed MAC Legislation May Increase Costs of Affected Generic Drugs By More Than 50 Percent Prepared for January 2015 Executive Summary MAC (Maximum Allowable Cost) is a savings tool used by Medicare,
More informationCRS Report for Congress Received through the CRS Web
CRS Report for Congress Received through the CRS Web Order Code RS20295 August 9, 1999 Outpatient Prescription Drugs: Acquisition and Reimbursement Policies Under Selected Federal Programs Heidi G. Yacker
More informationPotential Federal and State-by-State Savings if Medicaid Pharmacy Programs were Optimally Managed
Potential Federal and State-by-State Savings if Medicaid Pharmacy Programs were Optimally Managed February 2011 Commissioned by the Pharmaceutical Care Management Association Prepared by: Joel Menges Shirley
More informationIowa Medicaid Synopsis of Managed Medicaid Request for Proposal
Iowa Medicaid Synopsis of Managed Medicaid Request for Proposal The following information provides summary information of key aspects of the Iowa Medicaid Request For Proposal SOW for Capitated Managed
More informationSurvey of the Average Cost of Dispensing a Medicaid Prescription in the State of Alaska
Survey of the Average Cost of Dispensing a Medicaid Prescription in the State of Alaska Prepared for the Alaska Department of Health and Social Services August 17, 2012 Table of Contents CHAPTER 1: EXECUTIVE
More informationFederal Spending on Brand Pharmaceuticals. April 2011
Federal Spending on Brand Pharmaceuticals April 2011 Summary Avalere Health estimates that manufacturers of brand-name prescription drugs will receive about $777 billion in revenues from the sales of outpatient
More informationProvisions of the Medicare Modernization Act
Provisions of the Medicare Modernization Act Medicare Prescription Drug Modernization and Improvement Act of 2003 (MMA) Todd Whitney, FSA, MAAA Wakely Consulting Group Highlights of New Act New Rx Benefit
More informationOklahoma Health Care Authority
Oklahoma Health Care Authority It is very important that you provide your comments regarding the proposed rule change by the comment due date. Comments are directed to Oklahoma Health Care Authority (OHCA)
More informationTexas Vendor Drug Program. Drug Addition Process. Effective Date. December 2017
Texas Vendor Drug Program Drug Addition Process Effective Date December 2017 This is a working document to provide a resource to interested internal and external stakeholders. Questions or comments regarding
More informationCase 3:12-cv NJR-RJD Document 359 Filed 05/01/17 Page 1 of 100 Page ID #9373
Case 3:12-cv-00881-NJR-RJD Document 359 Filed 05/01/17 Page 1 of 100 Page ID #9373 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF ILLINOIS UNITED STATES OF AMERICA, and the ) STATES OF CALIFORNIA,
More informationEstablish fair elmbursements
Needed PBM (Pharmacy BeneFit Manager] ReForms - for patients NOW O j.imit purpose nd scope Require price transparency Establish fair elmbursements PBMs started as third party admintsbalors simply chargingan
More informationSteve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration
Medicaid Drug Rebates Steve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration Medicaid Drug Rebates History of Medicaid Drug Rebates and Preferred Drug Lists Affordable
More informationPharmacy Provider Liaison Minutes from Meeting on December 8, 2016
MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES Medical Services Administration Pharmacy Management Division Pharmacy Provider Liaison Minutes from Meeting on December 8, 2016 Attendees Ray Casambre,
More informationChapter 9 Medicaid and 340B
Chapter 9 Medicaid and 340B A. Introduction UPDATED 1. The complex intersection of Medicaid and 340B The intersection of 340B and Medicaid is one of the most complex and significant areas within any health
More informationRe: CMS 2238 FC (Final Rule: Medicaid Program; Prescription Drugs)
January 2, 2008 Reference No.: FASC08001 Kerry Weems Acting Administrator, Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200
More informationMICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES NOTICE OF PROPOSED POLICY
MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES NOTICE OF PROPOSED POLICY Public Act 280 of 1939, as amended, and consultation guidelines for Medicaid policy provide an opportunity to review proposed
More informationBERKELEY RESEARCH GROUP. Executive Summary
Executive Summary Within the U.S. healthcare system, the flow of dollars in the pharmaceutical marketplace is a complex process involving a variety of stakeholders and myriad rebates, discounts, and fees
More informationLEGISLATURE 2017 BILL. reporting by manufacturers and providing a penalty.
0-0 LEGISLATURE LRB-/ 0 AN ACT to create.0 of the statutes; relating to: prescription drug cost reporting by manufacturers and providing a penalty. Analysis by the Legislative Reference Bureau This bill
More informationPricing Chapter 10. Single Payment Amount applies to the allowed payment amount for an item furnished under a competitive bidding program.
Chapter 10 Contents Introduction 1. Fee Schedules 2. Reasonable Charges 3. Drug Pricing 4. Single Payment Amount 5. Individual Consideration Introduction Pricing Pricing for durable medical equipment,
More informationPricing Chapter Fee Schedules CMS Manual System, Pub , Medicare Claims Processing Manual, Chapter 20, 40.1, 50, 50.
Chapter 10 Contents Introduction 1. Fee Schedules 2. Reasonable Charges 3. Drug Pricing 4. Individual Consideration Introduction Pricing Pricing for durable medical equipment, prosthetics, orthotics and
More informationCenter for Medicaid, CHIP, and Survey & Certification SMDL# PPACA# 2. April 22, Re: Medicaid Prescription Drug Rebates
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850 Center for Medicaid, CHIP, and Survey & Certification
More informationMoving From PBM to PBA Model
Moving From PBM to PBA Model Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Pro Pharma Pharmaceutical Consultants, Inc. Under the preceptorship of Dr. Craig Stern
More informationMedicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary
Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary The Centers for Medicare & Medicaid Services (CMS) on February 2, 2012 published in the Federal Register a proposed rule
More informationWe applied the following methodology and assumptions changes to our original estimates:
333 Clay Street Suite 4330 Houston, TX 77002 USA Tel +1 713 658 8451 Fax +1 713 658 9656 April 1, 2013 milliman.com Ms. Barbara Maxwell Deputy Director Texas Association of Health Plans 1001 Congress Avenue,
More informationAnalysis of PBM Spread Pricing in New York Medicaid Managed Care 3 Axis Advisors LLC
1 EXECUTIVE SUMMARY Spread pricing is a core component of the traditional pharmacy benefit manager (PBM) business model. In a spread transaction, PBMs generate revenue by charging the payer one price for
More informationPrescription Drugs Spending Distribution and Cost Drivers. Steve Kappel January 25, 2007
Prescription Drugs Spending Distribution and Cost Drivers Steve Kappel January 25, 2007 Introduction Why Focus on Drugs? Compared to other health care spending: Even faster annual growth Higher reliance
More information(PDP) 2014 Summary of benefits for our Medicare prescription drug plans (Enhanced and Standard)
(PDP) 2014 Summary of benefits for our prescription drug plans (Enhanced and Standard) Contract S5540, Plans 004 and 002 January 1, 2014 December 31, 2014 U5073c, 8/13 Y0079_6249 CMS Accepted 09112013
More informationUnderstanding Pharmacy Benefit Management Services
Understanding Pharmacy Benefit Management Services Peter Cullen VP, Business Development and Strategic Initiatives March 12, 2014 Innovation Session Overview and Learning Objectives Session Overview: Provide
More informationNew York Institutes New Medicaid Drug Price Control Measures. State Budget Includes Medicaid Drug Expenditure Cap. FDA & Life Sciences Practice Group
FDA & Life Sciences Practice Group April 21, 2017 For more information, contact: John D. Shakow +1 202 626 5523 jshakow@kslaw.com Brian A. Bohnenkamp +1 202 626 5413 bbohnenkamp@kslaw.com Elizabeth F.
More informationPrescription Drug Event (PDE) Data: Source and Processing
Prescription Drug Event (PDE) Data: Source and Processing Barbara Frank, M.S., M.P.H. Director of Workshops, Outreach, & Research University of Minnesota Frequently Repeated Acronyms CMS Centers for Medicare
More informationJuly 2016 Medicaid Bulletin
July 2016 Medicaid Bulletin In this Issue...Page All Providers Consolidation of NCTracks Fax Numbers. 2 Manage Change Request and Reverification Application Process.... 2 Re-credentialing Due Dates for
More information340B Drug Program Compliance: Focus on Disproportionate Hospitals
340B Drug Program Compliance: Focus on Disproportionate Hospitals Part II: 340B Drug Program Compliance: Pharmacy Operations and the DSH January 29, 2014 1 Faculty Stephen J. Weiser, JD, LLM Director 312-403-4284
More informationExploring the Interaction between Medicare Part B and Medicare Part D
The National Medicare Prescription Drug Congress Exploring the Interaction between Medicare Part B and Medicare Part D Jennifer Breuer, Esq. Gardner, Carton & Douglas 191 N. Wacker Drive Chicago, IL 60606
More informationAn Introduction to and Updated Regarding the 340B Federal Drug Discount Program
An Introduction to and Updated Regarding the 340B Federal Drug Discount Program Chris Roberson, JD, MPH 317.871.0000 or 877.256.8837 Raphael Health Center Picture of CHC Describe how many centers and how
More informationSavings Generated by New York s Medicaid Pharmacy Reform
Savings Generated by New York s Medicaid Pharmacy Reform Sponsored by: Pharmaceutical Care Management Association Prepared by: Special Needs Consulting Services, Inc. October 2012 Table of Contents I.
More informationOverview of Coverage of Drugs Under the Medicaid Medical Benefit
Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008 Amanda Bartelme Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy Medical vs. Pharmacy
More informationMEDICARE PART D PRESCRIPTION DRUG EVENTS (PDE) RECONCILIATION
MEDICARE PART D PRESCRIPTION DRUG EVENTS (PDE) RECONCILIATION 2-06-15 Presented by: Alexander Luong, Pharm.D. Candidate 2015 University of the Pacific Preceptor: Dr. Craig Stern, Pharm.D. MBA President,
More informationTHIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE
THIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE Donna Lee Yesner Morgan Lewis and Bockius Phone : 202.739.5887 Email: dyesner@morganlewis.com www.morganlewis.com BACKGROUND In
More informationAMCP Guide to Pharmaceutical Payment Methods
AMCP Guide to Pharmaceutical Payment Methods EXECUTIVE EDITION AMCP Task Force on Drug Payment Methodologies October 2007 This AMCP Guide to Pharmaceutical Payment Methods was created by the Editor-in-Chief
More informationSurvey Analysis of January 2014 CMS Medicare Part D Proposed Rule
Survey Analysis of January 2014 CMS Medicare Part D Proposed Rule Prepared for: Pharmaceutical Care Management Association Prepared by: Stephen J. Kaczmarek, FSA, MAAA Principal and Consulting Actuary
More informationFraud, Waste and Abuse A Presentation for Network Providers
Fraud, Waste and Abuse A Presentation for Network Providers Presentation Topics TOPICS SLIDES Our Pledge 1 The Law 4-8 Definitions 9-12 Waste and Recovery 14-18 Recipient Fraud 19-25 Provider Fraud 26-28
More informationAppendix I: Data Sources and Analyses. Appendix II: Pharmacy Benefit Management Tools
Appendix I: Data Sources and Analyses This brief includes findings from analyses of the Centers for Medicare & Medicaid Services (CMS) State Drug Utilization Data 1 and CMS 64 reports for federal fiscal
More information340B Compliance, Audits & Opportunities
340B Compliance, Audits & Opportunities NW Ohio HFMA February 15, 2018 David Layne, CPA Manager HRSA Audits Bizzell Group-Silver Spring, Maryland Prior Hospital experience Many are pharmacists Experienced
More informationMedicare Part D Contract Analysis
Medicare Part D Contract Analysis Presented by: H. Edward Heckman, R.Ph., PAAS National 4:15 p.m. - 5:45 p.m., Tuesday, Ft. Lauderdale, Florida Evaluation # 05-136 This program is approved by NCPA for
More information340B Drug Pricing Program
340B Drug Pricing Program Mary Stepanyan, PharmD Candidate 2018 University of Southern California, School of Pharmacy Pro Pharma Pharmaceutical Consultants Under the preceptorship of Dr. Craig Stern WHY
More informationFraud, Waste and Abuse
Fraud, Waste and Abuse A Presentation for Network Providers Presented by: Pennsylvania and Northeast Presentation Topics TOPICS SLIDES Our Pledge 1 The Law 4-8 Definitions 9-12 Waste and Recovery 14-18
More informationHealth Reform Update: Focus on Prescription Drug Price Regulation
International Life Sciences Arbitration Health Industry Alert If you have questions or would like additional information on the material covered in this Alert, please contact the author: Joseph W. Metro
More informationBehavioral Health Parity and Medicaid
Behavioral Health Parity and Medicaid MaryBeth Musumeci Behavioral health parity refers to requirements for health insurers to cover mental health and substance use disorder services on terms that are
More informationM E N T A L H E A L T H P A R I T Y A N D A D D I C T I O N E Q U I T Y A C T ( M H P A E A )
H E A L T H W E A L T H C A R E E R M E N T A L H E A L T H P A R I T Y A N D A D D I C T I O N E Q U I T Y A C T ( M H P A E A ) N E W M E X I C O B E H A V I O R A L H E A L T H C O L L A B O R A T I
More informationCommon Managed Care Terms & Definitions
Contact Us: Email: info@emedbiz.com Phone: 561-430-2090 Fax: 561-430-2091 Website: www.emedbiz.com Common Managed Care Terms & Definitions Balance billing: The practice of billing a patient for the amount
More informationH.F. 3. Overview. Summary. Bill Summary. First engrossment. Liebling and others. Date March 11, 2019
Bill Summary Subject Authors Analyst OneCare Buy-In Liebling and others Randall Chun Date March 11, 2019 Overview This bill directs the commissioner of human services to make various changes in the delivery
More informationRe: CMS-1502-P (Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006)
BY ELECTRONIC DELIVERY Mark McClellan, Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200 Independence Avenue, S.W.
More informationOverview of the March 29, 2016 Final Rule on the Application of Mental Health Parity Requirements to Coverage Offered by Medicaid Managed Care
Overview of the March 29, 2016 Final Rule on the Application of Mental Health Parity Requirements to Coverage Offered by Medicaid Managed Care Organizations, the Children s Health Insurance Program, and
More information340B Program Update & Recommendations for Monitoring Program Compliance October
340B Program Update & Recommendations for Monitoring Program Compliance October 2 2014 Speaker Biography Ray Albertina Director Deloitte & Touche LLP +1 (314) 342 4984 ralbertina@deloitte.com Ray is a
More informationFinal Regulation on Mental Health Parity in Medicaid: NAMD Summary
Final Regulation on Mental Health Parity in Medicaid: NAMD Summary April 21, 2016 In April 2016, the Centers for Medicare and Medicaid Services (CMS) released a final regulation which implements mental
More informationDEFICIT REDUCTION ACT OF 2005: IMPLICATIONS FOR MEDICAID PREMIUMS AND COST SHARING CHANGES
February 2006 DEFICIT REDUCTION ACT OF 2005: IMPLICATIONS FOR MEDICAID On February 8, 2006 the President signed the Deficit Reduction Act of 2005 (DRA). The Act is expected to generate $39 billion in federal
More informationMedicare Part D: TrOOP (True Out-Of-Pocket) Costs
Medicare Part D: TrOOP (True Out-Of-Pocket) Costs Pantea Ghasemi, USC Pharm.D. Candidate of 2015 Preceptor Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. May 1, 2015 Objectives 1. Review background
More informationProjected Impacts of Adopting a Pharmacy Carve-In Approach Within Medicaid Capitation Programs
Projected Impacts of Adopting a Pharmacy Carve-In Approach Within Medicaid Capitation Programs Sponsored by: Medicaid Health Plans of America Prepared by: The Lewin Group Date: February 2011 Table of Contents
More informationThe Impact of the Medicare Prescription Drug Legislation on Pharmaceutical Revenues
The Impact of the Medicare Prescription Drug Legislation on Pharmaceutical Revenues Presented By: Jack Rodgers PricewaterhouseCoopers February 27, 2004 P w C Overview of Recent Medicare Act On December
More information4) We will not release any information identifying hospitals or individual respondents without obtaining prior consent.
Welcome! On July 13, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would substantially reduce how much Medicare Part B pays 340B hospitals for non-retail drugs under
More informationSDMC RETIREE HEALTH INSURANCE OPTIONS. Pre and Post Age 65
SDMC RETIREE HEALTH INSURANCE OPTIONS Pre and Post Age 65 This information has been provided to you to help you understand your retirement benefit options prior to meeting with the Benefits Staff. At your
More informationLITIGATING AWP. Mitch Lazris/Lyndon Tretter Hogan & Hartson L.L.P. November 15, 2002
LITIGATING AWP Mitch Lazris/Lyndon Tretter Hogan & Hartson L.L.P. November 15, 2002 Litigation Landscape Federal Gov t/states/private Class Actions Payment Systems Medicare (based on 95% of AWP) Medicare
More informationAverage Sales Price and Medicare Part B. Lisa C. McNair Senior Finance Manager Contracting & Reimbursement Indivior, Inc.
Average Sales Price and Medicare Part B Lisa C. McNair Senior Finance Manager Contracting & Reimbursement Indivior, Inc. May, 2016 Disclaimer The views and opinions expressed in this presentation are those
More information2007 State Perspectives Medicaid Pharmacy Policies and Practices
NOVEMBER 2007 2007 State Perspectives Medicaid Pharmacy Policies and Practices National Association of State Medicaid Directors An Affiliate of the American Public Human Services Association 2007 State
More informationMEDICAID AND BUDGET RECONCILIATION: IMPLICATIONS OF THE CONFERENCE REPORT
Updated January 2006 MEDICAID AND BUDGET RECONCILIATION: IMPLICATIONS OF THE CONFERENCE REPORT In compliance with the budget resolution that passed in April 2005, the House and Senate both passed budget
More informationBlueScript for Medicare Part D Option 1
Prescription Drug Plan for Medicare Beneficiaries BlueScript for Medicare Part D Option 1 S5904 2006 Summary of Benefits January 1, 2006 - December 31, 2006 State of Florida Section 1 - Introduction to
More informationMEDICARE PRESCRIPTION DRUGS and LOW-INCOME BENEFICIARIES
Figure 0 MEDICARE PRESCRIPTION DRUGS and LOW-INCOME BENEFICIARIES Diane Rowland, Sc.D. Executive Director Kaiser Commission on and Executive Vice President, Kaiser Family Foundation December 15, 2003 Figure
More informationState Pharmacy Assistance Programs: Additional Charts
State Pharmacy Assistance Programs: Additional Charts Thomas Trail Kimberley Fox Joel Cantor Mina Silberberg Stephen Crystal Trail, Fox, Cantor, Silberberg, and Crystal, State Pharmacy Assistance Programs:
More informationTHE OHIO DEPARTMENT OF MEDICAID
HEALTH WEALTH CAREER THE OHIO DEPARTMENT OF MEDICAID PHARMACY STAKEHOLDER ENGAGEMENT MEETING September 13, 2016 Presenter Scott Banken, Mercer WHY WHO HOW The ODM is conducting a Professional Dispensing
More informationWORKING WITH PRIVATE SECTOR PARTNERS TO MAXIMIZE MEDICARE SAVINGS PROGRAM AND PART D ENROLLMENT
WORKING WITH PRIVATE SECTOR PARTNERS TO MAXIMIZE MEDICARE SAVINGS PROGRAM AND PART D ENROLLMENT James M. Verdier Mathematica Policy Research, Inc. State Solutions Invitational Summit May 12, 2005 Washington,
More informationPayment Policy Pharmacy
Payment Policy Pharmacy 01/01/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck ND 58506-5585 701-328-3800 800-777-5033 www.workforcesafety.com 1 Copyright Notice The five character codes included in
More informationMarc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance
Marc Claussen, Chiesi USA, Director, Market Access Donna White, Chiesi USA, Sr. Director, Contracting and Compliance The views/observations expressed in this presentation are the personal views/observations
More informationCodebook for Medicaid Pharmacy Claims Data
Codebook for Medicaid Pharmacy Claims Data Enter X to Request Variable Number Variable Name Variable Label Variable Type Variable Length Valid Values 1 ALT_MBR_ID_ENCRYPT Alternate Member ID Encrypted
More informationDIR FEES: WHAT YOU NEED TO KNOW JULY 13, :00 10:00 AM
DIR FEES: WHAT YOU NEED TO KNOW JULY 13, 2017 9:00 10:00 AM ACPE UAN: 0107-9999-17-078-L04-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists: Upon completion of this CPE
More informationPharmacy Billing and Reimbursement
FSHP Disclosure Pharmacy Billing and Tara L McNulty RPhT, CPhT I, Tara McNulty, do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies
More informationStates and the Rising Cost of Pharmaceuticals: A Call to Action
States and the Rising Cost of Pharmaceuticals: A Call to Action January 11, 2017 3:30-4:30 pm ET Call-in: (877) 717-9270 Working Group on Pharmaceutical Drug Costs Supported by Kaiser Permanente & The
More informationHEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036
Curriculum Vitae HEATHER I. BATES Managing Director, BRG Health Analytics BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036 Direct: 202.480.2660 Cell: 202.641.1035 hbates@thinkbrg.com
More informationThis training will begin at 12:00pm ET. WebEx Technical Support: Or us at
This training will begin at 12:00pm ET WebEx Technical Support: 1-866-229-3239 Or e-mail us at nationalhivcenter@fenwayhealth.org Works with HIV/AIDS service organizations and community-based organizations
More informationAll Indiana Health Coverage Programs Physicians, Podiatrists, Dentists, Hospitals, Clinics, Mental Health Providers, and Pharmacies
Indiana Health Coverage Programs P R O V I D E R B U L L E T I N BT200132 AUGUST 10, 2001 To: All Indiana Health Coverage Programs Physicians, Podiatrists, Dentists, Hospitals, Clinics, Mental Health Providers,
More informationThis presentation provides an overview of the rate-setting methodology applicable to the HealthChoices Southeast (SE), Southwest (SW), Lehigh/Capital
This presentation provides an overview of the rate-setting methodology applicable to the HealthChoices Southeast (SE), Southwest (SW), Lehigh/Capital (LC), Northeast (NE) and Northwest (NW) zones. Please
More informationSUPPLEMENTAL REBATE AGREEMENT Company Name
Department Log # SUPPLEMENTAL REBATE AGREEMENT Company Name This Supplemental Rebate Agreement ( Agreement ) is dated as of this 1 st day of January, by and between the State of Utah Department of Health,
More informationPACE & Medicare Part D
PACE & Medicare Part D www.npaonline.org Shawn Bloom National PACE Association Shawnb@npaonline.org (703) 535-1518 PACE & Part D Session Objectives PACE Medication Regulations What Does Part D Cover What
More informationFederally Qualified Health Center (FQHC) / Rural Health Clinic (RHC) Prospective Payment System (PPS) Frequently Asked Questions.
Federally Qualified Health Center (FQHC) / Rural Health Clinic (RHC) Prospective Payment System (PPS) Frequently Asked Questions General 1. Is there language in our agreement around updated contracts with
More information3/5/2016. Tc 99m Healthcare Economics for Radiopharmacists. Payment options to promote stable and secure Tc 99m supply are constrained by
Disclaimer Healthcare Economics for Radiopharmacists Understanding the Radiopharmaceutical Supply Problem APhA 2016 Daniel J. Duvall, MD Chief Medical Officer CPI U.S. Representative to High Level Group
More informationSpecialty Pharmacy Trends: Payer and Industry Considerations for Specialty Pharmacies
Specialty Pharmacy Trends: Payer and Industry Considerations for Specialty Pharmacies September 18, 2017 Washington, DC Frier & Levitt, LLC Jonathan E. Levitt, JD Co-Founding Partner jlevitt@frierlevitt.com
More information